- Home
- MOLN vs FENC Comparison
MOLN vs FENC Comparison
Compare MOLN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- FENC
- Stock Information
- Founded
- MOLN 2004
- FENC 1996
- Country
- MOLN Switzerland
- FENC United States
- Employees
- MOLN N/A
- FENC N/A
- Industry
- MOLN
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOLN
- FENC Health Care
- Exchange
- MOLN Nasdaq
- FENC Nasdaq
- Market Cap
- MOLN 214.4M
- FENC 172.8M
- IPO Year
- MOLN 2021
- FENC 2001
- Fundamental
- Price
- MOLN $5.31
- FENC $5.97
- Analyst Decision
- MOLN
- FENC Strong Buy
- Analyst Count
- MOLN 0
- FENC 2
- Target Price
- MOLN N/A
- FENC $14.00
- AVG Volume (30 Days)
- MOLN 26.6K
- FENC 173.1K
- Earning Date
- MOLN 08-26-2024
- FENC 11-07-2024
- Dividend Yield
- MOLN N/A
- FENC N/A
- EPS Growth
- MOLN N/A
- FENC N/A
- EPS
- MOLN N/A
- FENC N/A
- Revenue
- MOLN $7,105,397.00
- FENC $49,348,000.00
- Revenue This Year
- MOLN N/A
- FENC $97.94
- Revenue Next Year
- MOLN $29.41
- FENC $11.50
- P/E Ratio
- MOLN N/A
- FENC N/A
- Revenue Growth
- MOLN N/A
- FENC 278.09
- 52 Week Low
- MOLN $3.32
- FENC $3.96
- 52 Week High
- MOLN $12.70
- FENC $11.92
- Technical
- Relative Strength Index (RSI)
- MOLN 43.84
- FENC 58.92
- Support Level
- MOLN $5.26
- FENC $5.84
- Resistance Level
- MOLN $5.65
- FENC $6.17
- Average True Range (ATR)
- MOLN 0.20
- FENC 0.36
- MACD
- MOLN -0.04
- FENC -0.04
- Stochastic Oscillator
- MOLN 6.85
- FENC 46.67
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.